Cardiac Pacemakers: Global Strategic Business Report

Global Cardiac Pacemakers Market to Reach $5.4 Billion by 2030

The global market for Cardiac Pacemakers estimated at US$4.3 Billion in the year 2022, is projected to reach a revised size of US$5.4 Billion by 2030, growing at a CAGR of 3.1% over the analysis period 2022-2030. Implantable Pacemaker Devices, one of the segments analyzed in the report, is projected to record 2.7% CAGR and reach US$3.3 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the External Pacemaker Devices segment is readjusted to a revised 3.7% CAGR for the next 8-year period.

The U.S. Market is Estimated at $1.2 Billion, While China is Forecast to Grow at 5.1% CAGR

The Cardiac Pacemakers market in the U.S. is estimated at US$1.2 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2030 trailing a CAGR of 5.1% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1.7% and 2.5% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 2.1% CAGR.

Select Competitors (Total 24 Featured) -

• Abbott Laboratories, Inc.
• Boston Scientific Corporation
• Cordis, a Cardinal Health company
• Medico SpA
• Medtronic PLC
• Shree Pacetronix Ltd.
• Vitatron Holding BV
• ZOLL Medical Corporation

What's New?

• Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
• Global competitiveness and key competitor percentage market shares
• Market presence across multiple geographies - Strong/Active/Niche/Trivial
• Online interactive peer-to-peer collaborative bespoke updates
• Access to digital archives and Research Platform
• Complimentary updates for one year